Gastric Cancer
Conditions
Interventions
None listed
Sponsors
Japan Clinical Cancer Research Organization (JACCRO)
Department of Medical Oncology, Kindai University Faculty of Medicine
Department of Genome Biology, Kindai University Faculty of Medicine
Department of Immunology and Genomic Medicine, and Center for Cancer Immunotherapy and Immunobiology (CCII), Kyoto University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who participated in the "Observational Study Including Biomarker Discovery of Nivolumab in Patients with Unresectable Advanced Gastric Cancer (DELIVER Study): JACCRO GC-08" and were able to submit a 500uL plasma sample prior to nivolumab treatment.
Exclusion criteria
Exclusion criteria: Patients who declined to participate in the "Observational Study of Nivolumab in Unresectable Advanced Gastric Cancer with Biomarker Discovery in Patients with Advanced Unresectable Gastric Cancer (DELIVER): JACCRO GC-08".
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Association between soluble PD-L1, soluble PD-1, and soluble CTLA-4 before nivolumab treatment and progression-free survival in patients with unresectable advanced gastric cancer | — |
Secondary
| Measure | Time frame |
|---|---|
| Relationship between soluble PD-L1, soluble PD-1, and soluble CTLA-4 and efficacy (overall survival, response rate, hyper progressive disease) and safety before nivolumab treatment in patients with unresectable advanced gastric cancer Relationship between soluble PD-L1, soluble PD-1, and soluble CTLA-4 and clinical background factors Relationship between soluble PD-L1, soluble PD-1, and soluble CTLA-4 and efficacy (progression-free survival, overall survival, | — |
Countries
Japan
Contacts
Public ContactHisato KAWAKAMI
Kindai University Faculty of Medicine Department of Medical Oncology
Outcome results
None listed